Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $17.41 and last traded at $16.99, with a volume of 111812 shares trading hands. The stock had previously closed at $16.26.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the company. Wedbush began coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price target on the stock. Guggenheim restated a "buy" rating and issued a $19.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, April 2nd. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $23.50.
Check Out Our Latest Report on MAZE
Maze Therapeutics Stock Performance
The company's fifty day simple moving average is $12.02.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).
Hedge Funds Weigh In On Maze Therapeutics
A number of large investors have recently modified their holdings of the business. New York State Common Retirement Fund bought a new position in Maze Therapeutics in the 1st quarter valued at about $25,000. Corebridge Financial Inc. acquired a new stake in Maze Therapeutics in the first quarter valued at approximately $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Maze Therapeutics during the first quarter valued at $57,000. Rhumbline Advisers bought a new position in Maze Therapeutics during the first quarter worth $80,000. Finally, Deutsche Bank AG bought a new position in Maze Therapeutics during the first quarter worth $98,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
